Market Overview

How UnitedHealth Should Give A Boost To Walgreens' 2017 Guidance

Share:
How UnitedHealth Should Give A Boost To Walgreens' 2017 Guidance
Related ESRX
Amazon Pharmacy Rumors Heating Up Again: Here's What We Know
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency
RGA Q3 2017 Letter - Amazon's Share Of E-Commerce = PayPal's Opportunity (Seeking Alpha)
Related RAD
Q3 13F Roundup: How Buffett, Einhorn, Paulson, And Others Adjusted Their Portfolio
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency
RGA Q3 2017 Letter - Amazon's Share Of E-Commerce = PayPal's Opportunity (Seeking Alpha)

Credit Suisse foresees an acceptable 2017 earnings per share guidance from Walgreens Boots Alliance Inc (NASDAQ: WBA) when its releases its results on Thursday. The opinion follows strong quarterly results reported by pharmacy benefit manager UnitedHealth Group Inc (NYSE: UNH).

Analyst's Take

Analyst Robert Willoughby sees the 12 percent increase in UnitedHealth's OptimumRx adjusted scripts as a positive for Walgreens given that the latter is UnitedHealth's preferred provider of 90-day prescriptions. The analyst noted that UnitedHealth's total healthcare membership rose 4.4 percent year-over-year to 48 million lives, with Medicare and Medicaid lives rising 8.4 percent and 9.1 percent, respectively.

Credit Suisse clarified that its earnings per share forecast for Walgreens does not include contribution from Rite Aid Corporation (NYSE: RAD)'s stores starting in January, Rite Aid's PBM business or any deleveraging or refinancing efforts.

Related Link: Walgreens-Rite Aid Merger Is In Some Trouble Thanks To Kroger

The firm noted that its model also doesn't include a UnitedHealth contribution or anything from its other deals across the supply chain. Additionally, Walgreens' role as the anchor pharmacy in Express Scripts Holding Company (NASDAQ: ESRX)'s Diabetes Care Value Program is not included, the firm noted.

Concluding, Credit Suisse said it may be difficult for Walgreens to guide to the high end at this juncture, given a host of variables in play. That said, the firm said it would revisit its $4.85 per share estimate when more clarity emerges.

As such, Credit Suisse has an Outperform rating and $95 price target on the shares of the company.

At time of writing, shares of Walgreens were down 1.43 percent at $76.96.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for ESRX

DateFirmActionFromTo
Oct 2017BairdMaintainsNeutral
Oct 2017Raymond JamesDowngradesMarket PerformUnderperform
Sep 2017RBC CapitalInitiates Coverage OnSector Perform

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Earnings Long Ideas News Guidance Price Target Previews Reiteration Best of Benzinga

 

Related Articles (ESRX + RAD)

View Comments and Join the Discussion!

Partner Center